source
- FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolioRegeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…
- AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor dealAbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…